Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7950654 | 0.92 | RAB9A (0.46) | RAB9AL3MBTL1PTPN1MEN1KMT2A | |
| SCHEMBL19416747 | 0.92 | RAB9A (0.48) | RAB9AL3MBTL1PTPN1MEN1KMT2A | |
| SCHEMBL7962255 | 0.90 | PTPN1 (0.43) | PTPN1 | |
| SCHEMBL3221066 | 0.84 | — | — | |
| SCHEMBL3221073 | 0.84 | — | — | |
| SCHEMBL7965835 | 0.83 | PTPN1 (0.43) | PTPN1 | |
| SCHEMBL19416770 | 0.82 | NPSR1 (0.41) | RAB9AL3MBTL1PTPN1ALDH1A1POLB | |
| SCHEMBL7965491 | 0.80 | MAPT (0.47) | ALDH1A1 | |
| SCHEMBL13491982 | 0.76 | — | — | |
| SCHEMBL13491980 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118711-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2018-05-03 | — | — | US | disclosed |
| US-9783521-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2017-10-10 | — | — | US | disclosed |
| EP-2310016-B1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORP (US) | 2017-10-04 | — | — | EP | disclosed |
| US-20140038951-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2014-02-06 | — | — | US | disclosed |
| US-8377930-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377930-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2013-02-19 | — | — | US | disclosed |
| WO-2010017236-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035872-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100035872-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118711-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | RAB9A 89/4885L3MBTL1 3487/4885PTPN1 2176/4885 |
| US-20140038951-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | RAB9A 89/4885L3MBTL1 3487/4885PTPN1 2176/4885 |
| US-20100035872-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | RAB9A 89/4885L3MBTL1 3487/4885PTPN1 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.